Research programme: sustained release therapeutics - Labopharm/Meda PharmaceuticalsAlternative Names: DDS-2001
Latest Information Update: 10 Oct 2011
At a glance
- Originator Labopharm
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 29 Nov 2004 This programme is still in active development
- 08 Aug 2003 Labopharm has completed feasibility and formulation studies for DDS 2001
- 11 Jul 2002 Preclinical trials in Undefined in Canada (unspecified route)